Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7769 participants.
Also called NCT02344290
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 7,769 participants
- Sponsor
- Registry
-
NCT02344290
-
- Other papers using this trial's data
- An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus
- Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function
- Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV
- Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
- Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)
- Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum
- Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial
- Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV
- Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial
- Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial
- Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk
- Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial
- Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV
- Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial
- Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort
- Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
- Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial
- Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
- Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial
- Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV
- The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial
- Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Botswana, Brazil, Canada, Haiti, India, Peru, Puerto Rico, South Africa, Spain, Thailand, Uganda, Zimbabwe
- Registry status
- Completed
Technical summary
Registry record NCT02344290. Randomized; quadruple masking; primary purpose prevention. Start 2015-03-26 (actual); primary completion 2023-08-21 (actual). Results posted on 2024-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
- Acronym
- REPRIEVE
- Condition
- HIV
- Condition
- Cardiovascular Diseases
- Intervention (Drug)
- Pitavastatin
- Intervention (Drug)
- Placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- Kowa Pharmaceuticals America, Inc.
- Collaborator
- Gilead Sciences
- Collaborator
- Massachusetts General Hospital
- Collaborator
- NEAT ID Foundation
Record details
- Record id
cardio:ct-nct02344290- Content hash
052e84277bd7673282331e6bd23478a556bab4886d9e0fdfba5e25fadd86b161